Our mission at MSK has always been to care for and cure people with cancer. As part of this goal, we’ve worked for decades to find new treatments. Many of our innovations and approaches have set the standard for care.
The MSK Lymphoma Service has one of the largest and most innovative clinical trial programs in the world. We offer a diverse range of treatment options for patients with Hodgkin and non-Hodgkin lymphoma. Because of our active clinical trial research program, we have helped to develop most of the lymphoma drugs that have improved patient outcomes and are currently FDA approved. Many of our clinical trials turn the latest discoveries from the laboratory into new treatments for patients with lymphoma.
Choosing MSK may give you access to new treatment options that are not yet readily available and could turn out to be tomorrow’s cures. We have extensive experience in matching patients with the clinical trials that will benefit them the most.
Prior Treatment (Relapsed/Refractory)
A Phase III Study of Rituximab with and without Copanlisib in Patients with Recurrent B-Cell Non-Hodgkin Lymphoma
Matthew J. Matasar
[Protocol 15-236]
A Phase I Study of ADCT-301 in Patients with Persistent or Recurrent Hodgkin or Non-Hodgkin Lymphoma
Steven M. Horwitz
[Protocol 15-300]
A Phase I Study of BTCT4465A Immunotherapy in Patients with Recurrent or Persistent B-cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Matthew J. Matasar
[Protocol 16-182]
A Phase III Study of Standard Immunochemotherapy with and without Copanlisib in Patients with Recurrent Non-Hodgkin Lymphoma
Matthew J. Matasar
[Protocol 16-873]
A Phase I Study of TTI-621Immunotherapy in Patients with Persistent or Recurrent Blood Cancers
Steven M. Horwitz
[Protocol 16-1347]
A Phase I Study of Immunotherapy with GWN323 Alone and with PDR001 in Patients with Advanced Cancers and Lymphomas
Alexander M. Lesokhin
[Protocol 16-1447]
A Phase I Study of “Armored” Genetically Modified T Cells to Treat Patients with Recurrent or Persistent Chronic Lymphocytic Leukemia
Jae Park
[Protocol 16-1570]
A Study of CA-4948 in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma
Anas Younes
[Protocol 18-053]
A Phase I Study of Oral RGX-104 Immunotherapy for Patients with Recurrent or Persistent Advanced Solid Tumors and Lymphoma
Michael A. Postow
[Protocol 17-006]
A Phase I Study of an Arginine Methyltransferase Inhibitor (PRMT5, GSK3326595) in Patients with Solid Tumors and Non-Hodgkin Lymphoma
Mrinal M. Gounder
[Protocol 17-188]
Untreated (Newly Diagnosed)
Prior Treatment (Relapsed/Refractory)
A Phase I Study of BTCT4465A Immunotherapy in Patients with Recurrent or Persistent B-cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Matthew J. Matasar
[Protocol 16-182]
A Phase I Study of Immunotherapy with GWN323 Alone and with PDR001 in Patients with Advanced Cancers and Lymphomas
Alexander M. Lesokhin
[Protocol 16-1447]
A Phase I Study of ME-401 in Patients with Recurrent or Persistent Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia or Follicular Lymphoma
[Protocol 16-1614]
A Phase III Study of Standard Immunochemotherapy with and without Copanlisib in Patients with Recurrent Non-Hodgkin Lymphoma
Matthew J. Matasar
[Protocol 16-873]
A Phase I Study of ADCT-301 in Patients with Persistent or Recurrent Hodgkin or Non-Hodgkin Lymphoma
Steven M. Horwitz
[Protocol 15-300]
A Phase III Study of Rituximab with and without Copanlisib in Patients with Recurrent B-Cell Non-Hodgkin Lymphoma
Matthew J. Matasar
[Protocol 15-236]
A Pilot Study of Ibrutinib in Patients with Evidence of Follicular Lymphoma after Initial Treatment
Ariela Noy
[Protocol 16-396]
A Phase I Study of Oral RGX-104 Immunotherapy for Patients with Recurrent or Persistent Advanced Solid Tumors and Lymphoma
Michael A. Postow
[Protocol 17-006]
A Phase II Study of Entinostat plus Pembrolizumab Immunotherapy for Recurrent or Persistent Lymphoma
Anas Younes
[Protocol 17-073]
A Phase I Study of an Arginine Methyltransferase Inhibitor (PRMT5, GSK3326595) in Patients with Solid Tumors and Non-Hodgkin Lymphoma
Mrinal M. Gounder
[Protocol 17-188]
A Phase I Study of “Armored” Genetically Modified T Cells to Treat Patients with Recurrent or Persistent Chronic Lymphocytic Leukemia
Jae Park
[Protocol 16-1570]
A Phase II Study of Atezolizumab Immunotherapy with or without Low-Dose Radiation Therapy for Patients with Recurrent or Persistent Advanced Follicular Lymphoma
M. Lia Palomba
[Protocol 17-360]
A Study of CA-4948 in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma
Anas Younes
[Protocol 18-053]
Prior Treatment (Relapsed/Refractory)
A Phase I Study of TTI-621Immunotherapy in Patients with Persistent or Recurrent Blood Cancers
Steven M. Horwitz
[Protocol 16-1347]
A Phase I Study of ME-401 in Patients with Recurrent or Persistent Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia or Follicular Lymphoma
[Protocol 16-1614]
A Phase I Study of an Arginine Methyltransferase Inhibitor (PRMT5, GSK3326595) in Patients with Solid Tumors and Non-Hodgkin Lymphoma
Mrinal M. Gounder
[Protocol 17-188]
A Phase I Study of MRG-106 in Patients with Various Recurrent or Persistent Lymphomas and Leukemias
Alison J. Moskowitz
[Protocol 18-082]
Prior Treatment (Relapsed/Refractory)
A Phase I Study of BTCT4465A Immunotherapy in Patients with Recurrent or Persistent B-cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Matthew J. Matasar
[Protocol 16-182]
A Phase III Study of Standard Immunochemotherapy with and without Copanlisib in Patients with Recurrent Non-Hodgkin Lymphoma
Matthew J. Matasar
[Protocol 16-873]
A Phase I Study of “Armored” Genetically Modified T Cells to Treat Patients with Recurrent or Persistent Chronic Lymphocytic Leukemia
Jae Park
[Protocol 16-1570]
A Phase I Study of ADCT-301 in Patients with Persistent or Recurrent Hodgkin or Non-Hodgkin Lymphoma
Steven M. Horwitz
[Protocol 15-300]
A Phase III Study of Rituximab with and without Copanlisib in Patients with Recurrent B-Cell Non-Hodgkin Lymphoma
Matthew J. Matasar
[Protocol 15-236]
A Phase I Study of ME-401 in Patients with Recurrent or Persistent Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia or Follicular Lymphoma
[Protocol 16-1614]
A Phase I Study of MRG-106 in Patients with Various Recurrent or Persistent Lymphomas and Leukemias
Alison J. Moskowitz
[Protocol 18-082]
A Phase I Study of an Arginine Methyltransferase Inhibitor (PRMT5, GSK3326595) in Patients with Solid Tumors and Non-Hodgkin Lymphoma
Mrinal M. Gounder
[Protocol 17-188]
Untreated (Newly Diagnosed)
A Phase III Study of Polatuzumab Vedotin with Standard Immunochemotherapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma
Matthew J. Matasar
[Protocol 18-230]
Prior Treatment (Relapsed/Refractory)
A Phase I Study of “Armored” Genetically Modified T Cells to Treat Patients with Recurrent or Persistent Chronic Lymphocytic Leukemia
Jae Park
[Protocol 16-1570]
A Phase I Study of BTCT4465A Immunotherapy in Patients with Recurrent or Persistent B-cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Matthew J. Matasar
[Protocol 16-182]
A Phase I/II Study of Brentuximab Vedotin plus Nivolumab Immunotherapy in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma
Alison J. Moskowitz
[Protocol 16-526]
A Phase I Study of ME-401 in Patients with Recurrent or Persistent Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia or Follicular Lymphoma
[Protocol 16-1614]
A Phase I Study of TTI-621Immunotherapy in Patients with Persistent or Recurrent Blood Cancers
Steven M. Horwitz
[Protocol 16-1347]
A Phase I Study of Immunotherapy with GWN323 Alone and with PDR001 in Patients with Advanced Cancers and Lymphomas
Alexander M. Lesokhin
[Protocol 16-1447]
A Phase II Study of Standard Therapies with or without Polatuzumab Vedotin in Patients with Recurrent or Persistent B-Cell Lymphomas
Matthew J. Matasar
[Protocol 15-170]
A Phase I Study of ADCT-301 in Patients with Persistent or Recurrent Hodgkin or Non-Hodgkin Lymphoma
Steven M. Horwitz
[Protocol 15-300]
A Phase I/II Study of INCB039110 pus Ibrutinib in Patients with Recurrent or Persistent Diffuse Large B-Cell Lymphoma
Paul A. Hamlin
[Protocol 17-190]
A Phase I Study of Immunotherapy with Genetically Modified T Cells to Treat Recurrent or Persistent B-Cell Non-Hodgkin Lymphoma
M. Lia Palomba
[Protocol 15-295]
A Phase I Study of Oral RGX-104 Immunotherapy for Patients with Recurrent or Persistent Advanced Solid Tumors and Lymphoma
Michael A. Postow
[Protocol 17-006]
A Phase I Study of an Arginine Methyltransferase Inhibitor (PRMT5, GSK3326595) in Patients with Solid Tumors and Non-Hodgkin Lymphoma
Mrinal M. Gounder
[Protocol 17-188]
A Phase I Study of REGN3767 and/or REGN2810 Immunotherapy in Patients with Advanced Lymphoma
M. Lia Palomba
[Protocol 17-421]
A Phase I Study of MEDI7247 in Patients with Recurrent or Persistent Diffuse Large B-Cell Lymphoma
Connie Lee Batlevi
[Protocol 18-220]
A Study of CA-4948 in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma
Anas Younes
[Protocol 18-053]
A Phase I Study of MRG-106 in Patients with Various Recurrent or Persistent Lymphomas and Leukemias
Alison J. Moskowitz
[Protocol 18-082]
A Phase III Study of CAR T-Cell Immunotherapy versus Standard Therapy in Patients with Recurrent or Persistent Diffuse Large B-Cell Lymphoma (ZUMA-7)
Miguel-Angel Perales
[Protocol 18-340]
Untreated (Newly Diagnosed)
A Pilot Study of Brentuximab Vedotin with Chemotherapy and Radiation Therapy in Early-Stage Poor-Risk Newly Diagnosed Hodgkin Lymphoma
Anita Kumar
[Protocol 13-034]
A Phase I Study of Nivolumab Immunotherapy plus Standard Chemotherapy for Newly Diagnosed High-Risk Hodgkin Lymphoma
Alison J. Moskowitz
[Protocol 16-1536]
Prior Treatment (Relapsed/Refractory)
A Phase I Study of ADCT-301 in Patients with Persistent or Recurrent Hodgkin or Non-Hodgkin Lymphoma
Steven M. Horwitz
[Protocol 15-300]
A Phase II Study of Pembrolizumab Immunotherapy plus Involved Site Radiation Therapy to Treat Early Recurrent or Persistent Hodgkin Lymphoma
[Protocol 17-054]
A Phase II Study of Entinostat plus Pembrolizumab Immunotherapy for Recurrent or Persistent Lymphoma
Anas Younes
[Protocol 17-073]
A Phase I Study of Nivolumab and Ipilimumab Immunotherapy for Advanced HIV-Related Solid Tumors, including Hodgkin Lymphoma
Mark A. Dickson
[Protocol 16-1286]
A Phase I Study of Immunotherapy with GWN323 Alone and with PDR001 in Patients with Advanced Cancers and Lymphomas
Alexander M. Lesokhin
[Protocol 16-1447]
A Phase I Study of Oral RGX-104 Immunotherapy for Patients with Recurrent or Persistent Advanced Solid Tumors and Lymphoma
Michael A. Postow
[Protocol 17-006]
A Phase II Study of Pembrolizumab Immunotherapy plus Chemotherapy followed by Autologous Stem Cell Transplantation for Recurrent or Persistent Hodgkin Lymphoma
Alison J. Moskowitz
[Protocol 18-160]
Untreated (Newly Diagnosed)
A Phase III Study of Ibrutinib Alone or with Venetoclax in Patients with Relapsed Mantle Cell Lymphoma
Gottfried von Keudell
[Protocol 18-157]
A Study of CA-4948 in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma
Anas Younes
[Protocol 18-053]
Prior Treatment (Relapsed/Refractory)
A Phase I Study of ADCT-301 in Patients with Persistent or Recurrent Hodgkin or Non-Hodgkin Lymphoma
Steven M. Horwitz
[Protocol 15-300]
A Phase I Study of BTCT4465A Immunotherapy in Patients with Recurrent or Persistent B-cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Matthew J. Matasar
[Protocol 16-182]
A Phase I Study of Immunotherapy with GWN323 Alone and with PDR001 in Patients with Advanced Cancers and Lymphomas
Alexander M. Lesokhin
[Protocol 16-1447]
A Phase I Study of an Arginine Methyltransferase Inhibitor (PRMT5, GSK3326595) in Patients with Solid Tumors and Non-Hodgkin Lymphoma
Mrinal M. Gounder
[Protocol 17-188]
A Phase I Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Recurrent or Persistent Mantle Cell Lymphoma
Anita Kumar
[Protocol 17-216]
A Study of CA-4948 in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma
Anas Younes
[Protocol 18-053]
A Phase III Study of Ibrutinib Alone or with Venetoclax in Patients with Relapsed Mantle Cell Lymphoma
Gottfried von Keudell
[Protocol 18-157]
Untreated (Newly Diagnosed)
Prior Treatment (Relapsed/Refractory)
A Phase I Study of an Arginine Methyltransferase Inhibitor (PRMT5, GSK3326595) in Patients with Solid Tumors and Non-Hodgkin Lymphoma
Mrinal M. Gounder
[Protocol 17-188]
Prior Treatment (Relapsed/Refractory)
Untreated (Newly Diagnosed)
Prior Treatment (Relapsed/Refractory)
A Phase I/II Study of Brentuximab Vedotin plus Nivolumab Immunotherapy in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma
Alison J. Moskowitz
[Protocol 16-526]
A Phase I Study of Duvelisib with Either Romidepsin or Bortezomib for Recurrent or Persistent T-Cell Lymphoma
Steven M. Horwitz
[Protocol 16-042]
A Phase I Study of PRT062070 in Patients with Persistent or Recurrent Chronic Lymphocytic Leukemia, Small Cell Lymphocytic Leukemia, or B-Cell Non-Hodgkin Lymphoma
Paul A. Hamlin
[Protocol 14-023]
A Phase I Study of ADCT-301 in Patients with Persistent or Recurrent Hodgkin or Non-Hodgkin Lymphoma
Steven M. Horwitz
[Protocol 15-300]
A Phase II Study of Ruxolitinib in Patients with Persistent or Recurrent T-Cell or NK-Cell Lymphoma
Alison J. Moskowitz
[Protocol 16-1542]
A Phase II Study of Romidepsin after Autologous Stem Cell Transplantation in Patients with T-Cell Non-Hodgkin Lymphoma
Steven M. Horwitz
[Protocol 13-020]
A Phase IIA Study of ALRN-6924 in Patients with Recurrent or Persistent Peripheral T-Cell Lymphoma
Steven M. Horwitz
[Protocol 16-1687]
A Phase I Study of Oral RGX-104 Immunotherapy for Patients with Recurrent or Persistent Advanced Solid Tumors and Lymphoma
Michael A. Postow
[Protocol 17-006]
A Phase I Study of an Arginine Methyltransferase Inhibitor (PRMT5, GSK3326595) in Patients with Solid Tumors and Non-Hodgkin Lymphoma
Mrinal M. Gounder
[Protocol 17-188]
A Phase I Study of MRG-106 in Patients with Various Recurrent or Persistent Lymphomas and Leukemias
Alison J. Moskowitz
[Protocol 18-082]
Untreated (Newly Diagnosed)
A Pilot Study of AVD plus Brentuximab Vedotin to Treat Stage II-IV HIV-Associated Hodgkin Lymphoma
Ariela Noy
[Protocol 13-079]
AIDS Malignancy Consortium 101: A Pilot Study to Assess Adding Ibrutinib to Standard R-EPOCH Treatment for AIDS-Related Lymphomas
Ariela Noy
[Protocol 17-543]
Prior Treatment (Relapsed/Refractory)
A Phase I Study of Nivolumab and Ipilimumab Immunotherapy for Advanced HIV-Related Solid Tumors, including Hodgkin Lymphoma
Mark A. Dickson
[Protocol 16-1286]
Prior Treatment (Relapsed/Refractory)
Prior Treatment (Relapsed/Refractory)
A Phase I Study of ADCT-301 in Patients with Persistent or Recurrent Hodgkin or Non-Hodgkin Lymphoma
Steven M. Horwitz
[Protocol 15-300]
A Phase III Study of Standard Immunochemotherapy with and without Copanlisib in Patients with Recurrent Non-Hodgkin Lymphoma
Matthew J. Matasar
[Protocol 16-873]
A Phase III Study of Rituximab with and without Copanlisib in Patients with Recurrent B-Cell Non-Hodgkin Lymphoma
Matthew J. Matasar
[Protocol 15-236]
A Phase I Study of “Armored” Genetically Modified T Cells to Treat Patients with Recurrent or Persistent Chronic Lymphocytic Leukemia
Jae Park
[Protocol 16-1570]
A Phase I Study of an Arginine Methyltransferase Inhibitor (PRMT5, GSK3326595) in Patients with Solid Tumors and Non-Hodgkin Lymphoma
Mrinal M. Gounder
[Protocol 17-188]
A Study of CA-4948 in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma
Anas Younes
[Protocol 18-053]
A Phase II Study of Standard Therapies with or without Polatuzumab Vedotin in Patients with Recurrent or Persistent B-Cell Lymphomas
Matthew J. Matasar
[Protocol 15-170]
A Phase I Study of ADCT-301 in Patients with Persistent or Recurrent Hodgkin or Non-Hodgkin Lymphoma
Steven M. Horwitz
[Protocol 15-300]
A Phase I Study of Duvelisib with Either Romidepsin or Bortezomib for Recurrent or Persistent T-Cell Lymphoma
Steven M. Horwitz
[Protocol 16-042]
A Phase I Study of BTCT4465A Immunotherapy in Patients with Recurrent or Persistent B-cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Matthew J. Matasar
[Protocol 16-182]
A Phase I Study of Nivolumab and Ipilimumab Immunotherapy for Advanced HIV-Related Solid Tumors, including Hodgkin Lymphoma
Mark A. Dickson
[Protocol 16-1286]
A Phase I Study of Nivolumab Immunotherapy plus Standard Chemotherapy for Newly Diagnosed High-Risk Hodgkin Lymphoma
Alison J. Moskowitz
[Protocol 16-1536]
A Phase I Study of “Armored” Genetically Modified T Cells to Treat Patients with Recurrent or Persistent Chronic Lymphocytic Leukemia
Jae Park
[Protocol 16-1570]
A Phase I Study of ME-401 in Patients with Recurrent or Persistent Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia or Follicular Lymphoma
[Protocol 16-1614]
A Phase IIA Study of ALRN-6924 in Patients with Recurrent or Persistent Peripheral T-Cell Lymphoma
Steven M. Horwitz
[Protocol 16-1687]
A Phase I/II Study of INCB039110 pus Ibrutinib in Patients with Recurrent or Persistent Diffuse Large B-Cell Lymphoma
Paul A. Hamlin
[Protocol 17-190]
A Phase I Study of REGN3767 and/or REGN2810 Immunotherapy in Patients with Advanced Lymphoma
M. Lia Palomba
[Protocol 17-421]
A Phase I Study of MRG-106 in Patients with Various Recurrent or Persistent Lymphomas and Leukemias
Alison J. Moskowitz
[Protocol 18-082]
A Study of CA-4948 in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma
Anas Younes
[Protocol 18-053]
